Showing results (61-70 of 149) with videos related to

Sort By:
Pageof 15
Clinical and Translational Science|July 16, 2024
Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazoleSylvia D Klomp, Anette Veringa, Jan-Willem C Alffenaar, et al.
Genes|March 29, 2023
Feasibility of Community Pharmacist-Initiated and Point-of-Care <i>CYP2C19</i> Genotype-Guided De-Escalation of Oral P2Y12 InhibitorsAmar D Levens, Melina C den Haan, J Wouter Jukema, et al.
Therapeutic Drug Monitoring|July 9, 2025
Effect of CYP3A4 Methylation on Tacrolimus PharmacokineticsKarel K M Koudijs, Oumaima Etsouli, Costanza L Vallerga, et al.
Pharmacogenomics|November 7, 2013
Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantationMarloes H ten Brink, Tom van Bavel, Jesse J Swen, et al.
The Pharmacogenomics Journal|August 13, 2022
Development of an extensive workflow for comprehensive clinical pharmacogenomic profiling: lessons from a pilot study on 100 whole exome sequencing dataAlireza Tafazoli, Maaike van der Lee, Jesse J Swen, et al.
Pharmacogenomics|April 1, 2015
FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritisCristina Lucía Dávila-Fajardo, Tahar van der Straaten, Rene Baak-Pablo, et al.
Pharmacotherapy|April 30, 2024
Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case-cohortEleonora Camilleri, Mira Ghobreyal, Mettine H A Bos, et al.
British Journal of Clinical Pharmacology|December 15, 2021
Pharmacogenomic testing in paediatrics: Clinical implementation strategiesCharlotte I S Barker, Gabriella Groeneweg, Anke H Maitland-van der Zee, et al.
Drug Discovery Today|June 13, 2021
Model-informed precision dosing to optimise immunosuppressive therapy in renal transplantationTom C Zwart, Henk-Jan Guchelaar, Paul J M van der Boog, et al.
The Pharmacogenomics Journal|February 5, 2019
Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumorsMichiel C Verboom, Jacqueline S L Kloth, Jesse J Swen, et al.
Pageof 15